65--NOI - Oxford Nanopore PromethION Flow Cells and cD

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH OLAO

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026Q00477

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Classification Code

6550

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents3
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, has issued a combined synopsis/solicitation under procurement identifier 75N98026Q00477 for the acquisition of Oxford Nanopore PromethION flow cells and cDNA-PCR sequencing kits. This procurement is specifically intended to support the National Institute on Aging’s Center for Alzheimer’s Disease and Related Dementias (CARD) in its ongoing long-read RNA sequencing project, which focuses on ROSMAP brain samples. The primary objective is to enable direct, matched comparison with previously generated long-read whole-genome sequencing data from the same samples, thereby advancing research into Alzheimer’s disease and related dementias. The scope of this procurement encompasses the supply of proprietary PromethION flow cells (FLO-PRO114M) and cDNA-PCR Sequencing Kit V14 (SQK-LSK114-XL), both manufactured exclusively by Oxford Nanopore Technologies Inc. These items are essential for the operation of CARD’s existing PromethION 48 sequencing infrastructure, ensuring compatibility and continuity with prior sequencing efforts. The expected deliverables are the specified flow cells and sequencing kits, which will be used for high-throughput, long-read RNA sequencing applications. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive, brand-name acquisition, in accordance with FAR Subpart 12.6 and FAR 6.302-3(a)(2)(ii), citing Oxford Nanopore Technologies Inc. as the sole source provider. The procurement will result in a Firm-Fixed-Price purchase order and is conducted under the streamlined procedures for commercial products or services, with the total value not expected to exceed the simplified acquisition threshold. No set-aside requirements or special considerations are indicated, as the acquisition is restricted to the proprietary products necessary for the project. The contracting entity is the NIH Office of Logistics and Acquisition Operations (OLAO), a federal office within the Department of Health and Human Services. The relevant classification codes for this procurement are NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing, 2022 version) and Product Service Code 6550. The primary point of contact for this opportunity is Nicholas S. Capobianco, who can be reached via email at [email protected]. The notice was posted on August 6, 2026, and remains active, with responses due by October 6, 2026. Interested parties can access further details and attachments via the SAM.gov opportunity ID fbbafc0f43334d45915479ec7505ba2e at https://sam.gov/opp/fbbafc0f43334d45915479ec7505ba2e/view. Contractors considering this opportunity should note that the requirement is strictly for Oxford Nanopore’s proprietary products, and the procurement is non-competitive due to the necessity for compatibility with existing NIH infrastructure and prior research data. The contract’s core elements—supply of specified sequencing consumables, support for Alzheimer’s research, and adherence to NIH’s technical requirements—will remain constant throughout the contract lifecycle.